Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -84 Thousand GBP | 17.65% |
| 2022 | -102 Thousand GBP | 47.69% |
| 2021 | -195 Thousand GBP | 25.0% |
| 2020 | -260 Thousand GBP | -59.51% |
| 2019 | -163 Thousand GBP | -255.24% |
| 2018 | 105 Thousand GBP | -97.91% |
| 2017 | 5.02 Million GBP | 0.0% |
| 2016 | - GBP | -100.0% |
| 2015 | 25 Thousand GBP | -99.42% |
| 2014 | 4.29 Million GBP | 0.0% |
| 2013 | - GBP | 0.0% |
| 2012 | - GBP | -100.0% |
| 2011 | 112 Thousand GBP | 0.0% |
| 2010 | - GBP | 0.0% |
| 2009 | - GBP | 0.0% |
| 2008 | - GBP | -100.0% |
| 2007 | 45 Thousand GBP | -32.84% |
| 2006 | 67 Thousand GBP | 0.0% |
| 2005 | 67 Thousand GBP | 4.69% |
| 2004 | 64 Thousand GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | -50 Thousand GBP | 0.0% |
| 2023 Q1 | - GBP | 100.0% |
| 2023 FY | -84 Thousand GBP | 17.65% |
| 2023 Q4 | -34 Thousand GBP | 0.0% |
| 2023 Q3 | - GBP | 100.0% |
| 2022 Q1 | - GBP | 100.0% |
| 2022 FY | -102 Thousand GBP | 47.69% |
| 2022 Q4 | -50 Thousand GBP | 0.0% |
| 2022 Q3 | - GBP | 100.0% |
| 2022 Q2 | -52 Thousand GBP | 0.0% |
| 2021 Q3 | - GBP | 100.0% |
| 2021 Q1 | - GBP | 100.0% |
| 2021 FY | -195 Thousand GBP | 25.0% |
| 2021 Q2 | -131 Thousand GBP | 0.0% |
| 2021 Q4 | -64 Thousand GBP | 0.0% |
| 2020 Q3 | - GBP | 100.0% |
| 2020 Q2 | -131 Thousand GBP | 0.0% |
| 2020 Q1 | - GBP | 100.0% |
| 2020 Q4 | -129 Thousand GBP | 0.0% |
| 2020 FY | -260 Thousand GBP | -59.51% |
| 2019 Q1 | - GBP | -100.0% |
| 2019 Q3 | - GBP | 100.0% |
| 2019 FY | -163 Thousand GBP | -255.24% |
| 2019 Q4 | -115 Thousand GBP | 0.0% |
| 2019 Q2 | -48 Thousand GBP | 0.0% |
| 2018 Q3 | 39.50 GBP | 203.85% |
| 2018 Q1 | 13.00 GBP | -99.48% |
| 2018 FY | 105 Thousand GBP | -97.91% |
| 2018 Q2 | 13.00 GBP | 0.0% |
| 2018 Q4 | 39.50 GBP | 0.0% |
| 2017 Q3 | 2500.00 GBP | 19900.0% |
| 2017 FY | 5.02 Million GBP | 0.0% |
| 2017 Q4 | 2500.00 GBP | 0.0% |
| 2017 Q1 | 12.50 GBP | 0.0% |
| 2017 Q2 | 12.50 GBP | 0.0% |
| 2016 FY | - GBP | -100.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2016 Q4 | - GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2016 Q3 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2015 FY | 25 Thousand GBP | -99.42% |
| 2015 Q3 | - GBP | -100.0% |
| 2015 Q2 | 12.50 GBP | 0.0% |
| 2015 Q1 | 12.50 GBP | -37.5% |
| 2014 Q2 | 2125.00 GBP | 0.0% |
| 2014 Q1 | 2125.00 GBP | 0.0% |
| 2014 Q4 | 20.00 GBP | 0.0% |
| 2014 FY | 4.29 Million GBP | 0.0% |
| 2014 Q3 | 20.00 GBP | -99.06% |
| 2013 Q3 | - GBP | 0.0% |
| 2013 Q1 | - GBP | 0.0% |
| 2013 Q4 | - GBP | 0.0% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2012 FY | - GBP | -100.0% |
| 2011 FY | 112 Thousand GBP | 0.0% |
| 2010 FY | - GBP | 0.0% |
| 2009 FY | - GBP | 0.0% |
| 2008 FY | - GBP | -100.0% |
| 2007 FY | 45 Thousand GBP | -32.84% |
| 2006 FY | 67 Thousand GBP | 0.0% |
| 2005 FY | 67 Thousand GBP | 4.69% |
| 2004 FY | 64 Thousand GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 209.431% |
| CSL Limited | 7.56 Billion USD | 100.001% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.56% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 2807.93% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.718% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.071% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -145.974% |
| Mesoblast Limited | -35.16 Million USD | 99.761% |
| Marizyme, Inc. | 457.7 Thousand USD | 118.353% |
| Genus plc | 178.7 Million USD | 100.047% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 120.48% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -663.636% |
| ContraFect Corporation | -154 Thousand USD | 45.455% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -68.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -962.29 Thousand USD | 91.271% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 78.323% |
| MultiCell Technologies, Inc. | 49.32 USD | 170416.302% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.209% |
| EV Biologics, Inc. | 48.9 Thousand USD | 271.779% |
| Q BioMed Inc. | -8988.00 USD | -834.579% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.297% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -444.606% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 220.0% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 32.395% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.858% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -1596.284% |
| Arch Therapeutics, Inc. | -2439.00 USD | -3344.034% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 227.799% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 159.786% |
| Neon Bloom, Inc. | - USD | Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.038% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 234.992% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 13.859% |
| GB Sciences, Inc. | -624.00 USD | -13361.538% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 2.357% |
| argenx SE | 1.1 Billion USD | 100.008% |
| HST Global, Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -40284.615% |
| Enzolytics Inc. | 30.7 Thousand USD | 373.544% |
| Resverlogix Corp. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 117.412% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.674% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.189% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 92.642% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 83.674% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 113.606% |
| ONE Bio Corp. | 20.12 Million USD | 100.417% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.021% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -848.509% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -0.18% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 86.67% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 108.502% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.874% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.545% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -609.759% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -74.061% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 147.576% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 147.576% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 106.189% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -189.655% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 118.665% |
| SYBLEU INC | 11.69 Thousand USD | 818.194% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 73.709% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 101.823% |
| Bioxytran, Inc. | -8285.00 USD | -913.881% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 77.48% |
| Neutra Corp. | 14.33 Thousand USD | 685.978% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -2.439% |
| PureTech Health plc | -1.6 Million USD | 94.76% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 91.61% |
| IXICO plc | 3.27 Million USD | 102.569% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 87.896% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 95.31% |
| CSL Limited | 7.7 Billion USD | 100.001% |
| Cellectis S.A. | 18 Thousand USD | 566.667% |